Access to Information Requests Completed - October 2012

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the month of October 2012

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2010-00149	Information regarding the product Cold & Stuffy Nose, DIN 02328402 by ACCUDIAL PHARMACEUTICAL INC.	Disclosed in part	71
A-2010-00432	Information regarding the product Victoza (liraglutide) by NOVO NORDISK CANADA INC.	Disclosed in part	4,947
A-2010-00853	Information regarding the product Plan B, DIN 02241674.	Disclosed in part	1,442
A-2010-01177	Information regarding the product Advanced Listerine, NPN 80003347.	Disclosed in part	95
A-2011-00248	All documents relating to information provided to Health Canada in 2010 regarding Electronic Health Information and Communication Technology (EHICT) projects funded by Canada Health Infoway Inc.	Disclosed in part	174
A-2011-00526	AERs for the product Tylenol. Report numbers: 000142836, 000143354, 000153102, 000153360, 000154039, 000154628, 000157747, 000159495, 000161907 and 000162116.	Disclosed in part	34
A-2011-00563	All documents considered and/or relied upon by the Pest Management Regulatory Agency (PMRA) in relation to the re-evaluation of Imazethapyr as detailed in the Proposed Re-evaluation Decision (PRVD2010-02) and the Re-evaluation Decision (RVD2010-12).	Disclosed in part	3,117
A-2011-00610	Documents regarding Tobacco manufacturer and importer, required to provide under clauses 23(a), 23(b) and 23(c) of the regulations, which reported that it promoted an accessory with a consumer tobacco product-related brand element. (Jan 1,2010 to Jun 30, 2011)	Disclosed in part	12
A-2011-01213	Information regarding the product OxyNeo by Purdue Pharma.	Disclosed in part	215
A-2011-01370	Information regarding the product Strepsils Sore Throat Blocked Nose, DIN 02238543 by RECKITT BENCKISER (CANADA) INC.	Disclosed in part	44
A-2011-01371	Information regarding the product REGULAR STRENGTH MUCOUS RELIEF CHEST, DIN 02353598 by Arrow OTC Company.	Disclosed in part	45
A-2011-01443	Information regarding the product Silica, NPN 02128586 by Natural Factors Nutritional Products Limited.	Disclosed in part	21
A-2011-01458	All emails of Marlene Smith. (Apr 1, 2011 to Dec 1, 2011).	Disclosed in part	4,758
A-2011-01462	All email of Jim Wolfe between Doug Mercer, Derek Thompson, Diane McDonald (West Region Tribal Council Health Department) and grand Chief Ron Evans (Assembly of Manitoba Chiefs), Gloria Rach (Dakota Ojibwe Health Services) and Grand Chief Derek Nepinak (Assembly of Manitoba Chiefs). (Apr 1, 2010 to Dec 1, 2011).	Disclosed in part	1,430
A-2011-01468	All emails of Scott Smukowich. (Mar 1, 2011 to Dec 1, 2011).	Disclosed in part	5,092
A-2011-01476	Information regarding the NPN 80017305.	Disclosed in part	22
A-2011-01602	Documents about the whole wheat flour standard for food labels. (Jan 1, 2011 to Dec 31, 2011).	Disclosed in part	6
A-2011-01606	AERs for the product Perindopril. Report numbers: 000352844, 000352870, 000370698, 000370946, 000378346, 000373538, 000376185, 000375969 and 000368287.	Disclosed in part	31
A-2011-01613	AERs for the product Gliclazide. Report numbers: 000369281, 000376436 and 000376931.	Disclosed in part	7
A-2011-01614	AERs for the product Perindopril/Indapamide. Report numbers: 000375460, 000375967 and 000376541.	Disclosed in part	18
A-2012-00005	AERs for the product Aspirin. Report numbers: 000385693, 000388022, 000392054 and 000398300.	Disclosed in part	37
A-2012-00046	All interdepartmental and interagency correspondence relating to the concentrations of herbicide residues and metabolites in livestock feeds, including novel feeds. (Apr 4, 2007 to April 5 2012).	Disclosed in part	109
A-2012-00049	AERs for the product Cipro. Report numbers: 000386472, 000389730 and 000391074.	Disclosed in part	7
A-2012-00062	AERs. Report numbers: 000391677, 000380435, 000393420, 000383228, 000381020, 000384732, 000388022, 000399067, 000399061 and 000396845.	Disclosed in part	64
A-2012-00075	Copy of all the incident reports in Quebec related to consumer products in 2011.	Disclosed in part	455
A-2012-00082	AERs for the product APTIVUS. Report numbers: 000358140, 000211925, 000207936 and 000203436.	Disclosed in part	48
A-2012-00083	AER for the product VIRAMUNE. Report number: 000329451.	Disclosed in part	10
A-2012-00090	Testing results for arsenic in juice. (Apr 27, 2010 to Apr 26, 2012).	Disclosed in part	26
A-2012-00108	A list of the studies that were submitted to the Pest Management Regulatory Agency (PMRA) and/or were reviewed, considered, and/or relied upon during its initial registration of Horizon 240EC Herbicide. All notes, and memoranda prepared by the PMRA during its initial registration of Horizon 240EC Herbicide.	Disclosed in part	325
A-2012-00119	Documents regarding whether the health study on industrial wind turbines will be conducted through an academic institution and whether the research has undergone ethics approval.	All exempted	0
A-2012-00149	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product Align Urethral Support System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	64
A-2012-00206	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product Monarc Subfascial Hammock. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	140
A-2012-00212	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product Sparc Sling System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	46
A-2012-00240	User Manual or patient leaflet for Avaulta Plus Biosynthetic Support System. (Jan 1, 1996 to May 7, 2012).	All disclosed	65
A-2012-00243	User Manual for Avaulta Solo Support System. (Jan 1, 1996 to May 7, 2012).	All disclosed	58
A-2012-00244	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product Pelvicol. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	18
A-2012-00246	User Manual for Pelvicol. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	18
A-2012-00276	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product TVT Secur System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	77
A-2012-00335	Documents regarding the possible reduction of Canada Health Transfers (CHT) from the Federal Government. (Jun 1, 2004 to May 4, 2012).	Disclosed in part	160
A-2012-00361	Information detailing the number of people licensed to grow medical marihuana and the number of people authorized to possess medical marihuana within the cities of Vernon, Penticton and Kelowna, British Columbia (as well as the province as a whole). (May 25, 2012 to Jun 5, 2012).	All disclosed	1
A-2012-00419	Any Health Canada initiated health study proposed and/or existing relating to wind turbines. (Jan 1, 2012 to Jun 15, 2012).	Disclosed in part	334
A-2012-00423	All documents that relate to communications between Health Canada and Howe Gastmeier Chapnik Limited (or any affiliated organizations). (Jan 1, 2009 to Jun 15, 2012).	Disclosed in part	418
A-2012-00440	Information regarding the product Kava Kava, NPN 80029817 by Life Choice Ltd.	Disclosed in part	115
A-2012-00443	Information regarding the product Jointhealth Plus Antioxidants, NPN 80032238 by Membrell, LLC.	Disclosed in part	61
A-2012-00444	Information regarding the product 750 Mg Glucosamine And Eggshell, NPN 80023574 by Natural Factors Nutritional Products Limited.	Disclosed in part	106
A-2012-00445	Information regarding the product 750 Mg Glucosamine And Eggshell, NPN 80023555 by WN Pharmaceuticals Ltd.	Disclosed in part	99
A-2012-00450	Information regarding the product Life Choice Gaba; Doctor'S Choice Gaba, NPN 80029502 by Life Choice Ltd.	Disclosed in part	118
A-2012-00451	Information regarding the product Gh Freak, NPN 80029890 by PharmaFreak Technologies Inc.	Disclosed in part	65
A-2012-00461	Briefing notes written for the Minister on electronic cigarettes (e-cigarettes). (Jun 20, 2009 to Jun 21, 2012).	No records exist	0
A-2012-00470	Information regarding the product EXTRA STRENGTH TYLENOL COMPLETE COLD, COUGH & FLU, DIN 02347660.	Disclosed in part	50
A-2012-00471	AERs for the product Humira. Report numbers: 000374365, 000376049, 000378864, 000379428, 000379301 and 000379094.	Disclosed in part	26
A-2012-00531	Documents regarding Health Canada' inquiry of products manufactured by Standard Innovation Corporation. The claim number is: CPS-SPC 001.03.	Disclosed in part	53
A-2012-00538	AERs for the product Isentress. Report numbers: 000380828, 000387924 and 000398697.	Disclosed in part	12
A-2012-00584	AERs for the product Aspirin. Report numbers: 000406588, 000414061, 000414071, 000414160, 000414290, 000415683, 000416085, 000416087 and 000420276.	Disclosed in part	104
A-2012-00589	All documents about Johnson & Johnson and Schedule F of the Food and Drugs Act (as laid out in the Budget Implementation Act, 2012). (Jun 1, 2011 to May 1, 2012)	Disclosed in part	13
A-2012-00609	All documents that were generated while processing and handling the petition presented to the House of Commons on May 4, 2012 by Mr. Claude Gravelle (Nickel Belt). The petition called on the Minister of Health and the House of Commons to pass a Bill, an act respecting a national strategy for dementia.	All disclosed	35
A-2012-00617	All documents that relate to noise and/or low frequency noise conference attended by Health Canada representatives. (Jan 1, 2012 to July 19, 2012).	Disclosed in part	71
A-2012-00661	All documents regarding any focus groups, polling or testing done of the images for the new cigarette warning labels. (Jan 1, 2011 to Aug 1, 2012).	All disclosed	241
A-2012-00693	All documents created in preparation, handed over during, and in the purpose of follow-up for the meeting between the Canadian Partnership against Cancer and Abby Hoffman and Leah Canning held on July 13, 2011.	Disclosed in part	131
A-2012-00771	All documents regarding the keepsake, entertainment, and 3D ultrasound industry in Canada. (Apr 1, 2012 to Aug 9, 2012).	Disclosed in part	37
A-2012-00823	Documents regarding the New Drug Submission (NDS) submitted by Frank W. Horner Limited ("Horner") on or about September 15, 1961 for TALIMOL (Thalidomide).	Disclosed in part	106
A-2012-00830	Information regarding the importations/exportations, per quarter, for the sales of: Cigar (In sticks), Snuff (in Kilo), Chewing Tobacco (in Kilo) and Pipe Tobacco (in Kilo), cigarettes (in sticks, roll your own tobacco (in Kilo)). (Apr 1, 2005 to Aug 20, 2012).	Disclosed in part	43
A-2012-00833	All documents created in preparation, handed over during, and in the purpose of follow-up after the meeting between the Canadian Partnership Against Cancer and Leona Aglukkaq, Abby Hoffman, Leah Canning, Robert Shearer, and Kim Elmslie, held January 27, 2011.	Disclosed in part	82
A-2012-00834	All documents created in preparation, handed over during, and in the purpose of follow-up after the meeting between the Canadian Partnership Against Cancer and Glenda Yeates, Anne Marie Robinson and Abby Hoffman, held December 20, 2010.	Disclosed in part	115
A-2012-00863	A copy of letter from Health Canada to Novopharm approving its product called Novo-Norflaxin. Letter issued during the time of the proceeding occurring between Dec 3, 1993 and Aug 14, 1998.	Disclosed in part	1
A-2012-00869	All correspondence between the Pest Management Regulatory Agency (PMRA) and 1,4 Group Inc. in relation to the notification that its registrations of PIN NIP 98% CIPC Technical (Reg. No. 30313) and PIN NIP 98% CIPC (Reg. No. 30320) are invalid and removed from the Register.	Disclosed in part	9
A-2012-00875	AERs. Report numbers: 000411859 and 000418477.	Disclosed in part	15
A-2012-00881	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of August 2012.	Disclosed in part	31
A-2012-00882	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during August 2012.	All disclosed	2
A-2012-00887	All contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of August 2012.	All disclosed	14
A-2012-00889	All briefing materials created for the minister and/or deputy minister on concurrent outbreaks of Ebola in Uganda and the Democratic republic of Congo. (Apr 1, 2012 to Sep 11, 2012).	No records exist	0
A-2012-00894	Product Monograph for the product Vasotec (sodium enalapril) by MERCK CANADA INC.	All disclosed	317
A-2012-00895	A listing of the Access to Information requests submitted to Health Canada. (Aug 1, 2012 to Aug 31, 2012).	Disclosed in part	13
A-2012-00899	All approved Product Monographs for the product Heparin by Pharmaceutical Partners of Canada.	No records exist	0
A-2012-00900	All approved Product Monographs for the product Heparin by Hospira.	No records exist	0
A-2012-00909	List of inspections carried out by Health Canada in 2011 of drug manufacturers in foreign countries who export medicines and/or medicinal ingredients to Canada.	All disclosed	3
A-2012-00911	The most recent estimate of the percentage of medicines and/or medicinal ingredients in the Canadian market that is imported.	No records exist	0
A-2012-00912	Provide any departmental guidance or standards on the frequency with which Health Canada expects to conduct inspections of drug manufacturers in Canada and (if different) in foreign countries.	No records exist	0
A-2012-00914	Information regarding the product Cinryze.	All exempted	0
A-2012-00916	Information regarding the product Octagam 10%.	All exempted	0
A-2012-00920	AER for the product Cipro. Report number: 000425109.	Disclosed in part	1
A-2012-00921	AER for the product Diane-35. Report number: 000428568.	Disclosed in part	3
A-2012-00922	AERs for the product Gadovist. Report numbers: 000425219 and 000430553.	Disclosed in part	3
A-2012-00923	AER for the product Kogenate. Report number: 000425137.	Disclosed in part	2
A-2012-00924	AER for the product Magnevist. Report number: 000425510.	Disclosed in part	1
A-2012-00926	AERs for the product Xarelto. Report numbers: 000424506, 000427140, 000427457 and 000428190.	Disclosed in part	6
A-2012-00927	AER for the product Yasmin. Report number: 000430605.	Disclosed in part	1
A-2012-00928	AERs for the product Yaz. Report numbers: 000427422 and 000428936.	Disclosed in part	2
A-2012-00935	Your estimates of the amounts of all kinds of radiation (resulting from the March 2011 Japan quake) in fish products (local or other) available to and consumed by Canadians, and the level of risk to these consumers, as well as the general radiation risk to Canadian' health.	No records exist	0
A-2012-00943	AER. Report number: 000324764.	Disclosed in part	1
A-2012-00945	All approved Product Monographs for the product Midazolam by Apotex.	All disclosed	42
A-2012-00946	All approved Product Monographs for the product Midazolam by Novopharm.	All disclosed	64
A-2012-00950	What were the average wait times for applications under the Marihuana Medical Access Regulations during the following fiscal years 2008/2009, 2009/2010 and 2010/2011?	No records exist	0
A-2012-00956	All internal memos within the Consumer Product Safety Directorate concerning the development and/or intention of the committee outlined under Section 67. (1) of the Canada Consumer Product Safety Act (CCPSA).	All disclosed	14
A-2012-00961	Product Monograph for the product Atropine Sulfate 0.1mg/ml, DIN 00328154.	No records exist	0
A-2012-00962	AERs for the products PregVit and PregVit folic 5. Report numbers: 000305588, 000368506, 000368518 and 000382260.	Disclosed in part	9
A-2012-00964	AER for the product Prevegyne. Report number: 000382631.	Disclosed in part	1
A-2012-00970	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during September 2012.	All disclosed	3
A-2012-00973	Information regarding the Risk Management Plan for OXYNEO by Perdue Pharma.	No records exist	0
A-2012-00981	AER for the product Avelox. Report number: 000434261.	Disclosed in part	1
A-2012-00982	AER for the product Betaseron. Report number: 000436393.	Disclosed in part	4
A-2012-00984	AERs for the product Cipro. Report numbers: 000435876 and 000437160.	Disclosed in part	1
A-2012-00985	AERs for the product Magnevist. Report numbers: 000435533, 000437808 and 000438614.	Disclosed in part	5
A-2012-00986	AERs for the product Mirena. Report numbers: 000435397, 000435839, 000436270 and 000457904.	Disclosed in part	4
A-2012-00988	AER for the product Primovist. Report number: 000434450.	Disclosed in part	2
A-2012-00989	AERs for the product Xarelto. Report numbers: 000438626 and 000439111.	Disclosed in part	3
A-2012-00990	AER for the product Yasmin. Report number: 000433361.	Disclosed in part	2
A-2012-01001	All documents related to Ministerial Loan Guarantees for mortgages for individual at the Woodstock First Nation in New-Brunswick, including any records related to defaults on payments or non-payments by recipients of Ministerial Loan Guarantees.	No records exist	0
A-2012-01002	All notifications of loans default, claim to Department of Indian Affairs and Northern Development (DIAND) for payment forms and supporting documentation, and repayment agreements related to arrears and defaults by Ministerial loan guarantee borrowers at the Woodstock First Nation in New Brunswick.	No records exist	0
A-2012-01010	Information regarding lawsuits that were launched from 2008-2012 by patients against doctors for malpractice with regards specifically to surgeons, and the total legal cost spent by Health Canada to legal firms or outside council in response to the lawsuits of malpractice.	No records exist	0
A-2012-01012	Statistics on Health Canada employee representation in the groups designated by the Employment Equity Act in the Quebec region for the years 2009 to 2011.	No records exist	0
A-2012-01015	AERs for the product Gadovist. Report numbers: 000437510, 00437522 and 000438279.	Disclosed in part	3
A-2012-01036	Product Monograph for the product Triferexx 150.	No records exist	0